Drug Profile
TGFb/retinoic acid nanocapsules - TherapyX
Alternative Names: TGFβ-NanoCap®; TreXTAMLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator TherapyX
- Class Anti-inflammatories; Cyclohexanes; Retinoids; Small molecules; Transforming growth factors
- Mechanism of Action Retinoic acid receptor agonists; Transforming growth factor beta type I receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 28 Feb 2022 Discontinued - Preclinical for Inflammatory bowel diseases in USA (PO) (TherapyX pipeline, February 2022)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (PO)
- 01 May 2020 Therapyx plans a clinical trial for inflammatory bowel disease